Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q1 2021 · 10-Q
Revenue$22.02K$22.02K+28.7% vs Q1 2020 Net Income-$34.02M-$34.02MN/M vs Q1 2020 EPS Diluted$0.00$0.00— vs Q1 2020 Gross Profit$16,389+38.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Operating Cash Flow-$594,333N/M Free Cash Flowderived-$604,283— Margins · derivedGross margin74.4%+5.3 pt vs Q1 2020
Operating margin-2457.4%−1346.8 pt vs Q1 2020
Net margin-154457.9%
ended Mar 31, 2021 · filed Sep 17, 2021 · 170 d after period end